CONMED Corporation Announces Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
CONMED (CNMD) PT Raised to $158 at Needham & Company
October 28, 2021 6:22 AM EDTNeedham & Company analyst Mike Matson raised the price target on CONMED (NASDAQ: CNMD) to $158.00 (from $150.00) while maintaining a Buy rating.
The analyst commented, "CNMD's 3Q21 revenue missed and EPS beat consensus. Management guided to the low-end of its prior revenue guidance range and... More
Conmed (CNMD) Tops Q3 EPS by 4c
October 27, 2021 4:24 PM EDTConmed (NASDAQ: CNMD) reported Q3 EPS of $0.80, $0.04 better than the analyst estimate of $0.76. Revenue for the quarter came in at $248.8 million versus the consensus estimate of $255.53 million.
GUIDANCE:
Conmed sees FY2021 EPS of $3.18-$3.23, versus the consensus of $3.19.
For earnings history and earnings-related data on Conmed (CNMD) click here.
... More


